Book Value per Share: Oruka Therapeutics Inc (ORKA)

Symbol and logo of brand Oruka Therapeutics Inc (ORKA)

Oruka Therapeutics Inc (ORKA) specializes in creating innovative skin health solutions. This asset price chart on GURU.Markets, where the current figure is 18.10, demonstrates business stability amid minimal external political pressure and an absence of trade restrictions. Simultaneously, the company is optimizing production processes by implementing modern filters and conserving water resources during protein synthesis.

ORKA Oruka Therapeutics, Inc. Share Book Value (09/04/2024 - 10/30/2026)

Summary analytical data breakdowns for orukatx.com (ORKA)

- current quotes and average value forecast:
Price Chart Oruka Corp|ORKA - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Capitalization Oruka Therapeutics Inc|ORKA - Enterprise Value
- business book valuation details:
Net Assets per Single Share Oruka Therapeutics|ORKA - Net Asset Value|Market Capitalization to Book Value Ratio orukatx.com|ORKA - Aggregate Asset Value
- debt level and financial liquidity data:
Total Debt to Capital Oruka Therapeutics Inc|ORKA - Long-Term Debt to Capital|Short-Term Debt to Equity Oruka Therapeutics|ORKA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Oruka Therapeutics Inc|ORKA - Company Long-Term Liabilities|Company Short-Term Debts Oruka Therapeutics|Quick Liquidity Indicator orukatx.com
- earnings and multiples data:
ORKA - Final Profit
General company analysis:ORKA - Oruka Corp
Manufactured products of Oruka Therapeutics

The book value per share reflects the scale of Oruka Therapeutics Inc (ORKA) net assets minus all liabilities. This metric is calculated as the difference between total assets and debts, divided by the number of shares. By analyzing the historical change in book value per share, an investor assesses the real value of their ownership stake. For a biotech company, this indicator confirms the cash runway available to fund R&D and clinical trials. Growth in this metric signals the business's financial stability during the drug development period.

Competitor analysis

KRYS - Net Assets per Single Share|APGE - Book Value per Share|ARQT: Book Value per Share|vcel.com (VCEL) - Book Value per Share|Net Assets per Single Share Sanara MedTech, Inc.|DBV Technologies SA - Share Book Value|Book Value per Share SLSN|DERM (journeymedicalcorp.com) - Accounting Value of a Share|Book Value per Share FBRX (Forte Biosciences, Inc.)|Book Value per Share empro.my EMPG|SLGL - Net Assets per Single Share|Accounting Value of a Share AXIL (AXIL Brands, Inc.)|Medicus Pharma Limited (MDCX) - Net Assets per Single Share|Accounting Value per Share Verrica Pharmaceuticals Inc.|HOTH (Hoth Therapeutics Inc.) - Book Value per Share|Book Value per Share Biofrontera Inc|Accounting Value per Share VYNE (VYNE Therapeutics)|SNOA (sonomapharma.com) - Accounting Value of a Share|Net Assets per Single Share Quoin Pharmaceuticals Ltd. QNRX|Net Assets per Share Azitra Corporation (AZTR)|DRMA - Net Assets per Single Share|ELAB - Book Value per Share|RVNC: Book Value per Share